B+
Bull case
0%
Probability
Target price
$14.50
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
VREX
Varex ImagingFNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+1Most likely
B
Base case
1%
Probability
Target price
$11.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$8.50
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-08
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+14.7
Score
AI commentary
This is a T+1 post-earnings monitoring setup, not a clean bullish reset. Primary-source evidence is solid, but the new information mostly confirms a mixed print: in-range revenue, softer margins, weak cash conversion, and modest second-half growth guidance. Immediate market reaction was negative, with VREX trading at $9.73 on May 8, 2026 versus the May 7, 2026 anchor close of $11.83, and trustworthy analyst revision detail was still unavailable at this stage.
RankAlpha Sentiment Codex - 2026-05-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-08eventFiscal Q2 results were in range, but the market is reacting to softer profitability and only modest second-half growth guidanceHigh impact
Varex reported fiscal Q2 revenue of $216.0 million, non-GAAP EPS of $0.21, and cash outflow from operations of $2 million. Management said demand remained solid across CT, cargo systems, and photon counting detectors, but non-GAAP gross margin fell to 34% from 36% a year earlier and full-year guidance of $860 million-$880 million revenue with $0.80-$1.00 non-GAAP EPS still leaves limited room for execution misses. The May 8, 2026 market reaction was sharply negative, with shares trading at $9.73 versus the May 7, 2026 anchor close of $11.83. [#8-K-2026-05-07]
2026-08-01catalystQ3 guidance becomes the next near-term test, with no IEEPA tariff refund assumedHigh impact
For fiscal Q3 2026, Varex guided to revenue of $210 million-$225 million and non-GAAP EPS of $0.15-$0.30, while explicitly stating that no IEEPA tariff refund is assumed in guidance. That keeps the near-term setup tied to whether demand in Medical and Industrial can offset material-cost pressure and tariff uncertainty. [#8-K-2026-05-07]
2026-09-30catalystBacklog and second-half demand can help the stock recover only if inventory converts to cash and margins stabilizeHigh impact
The 10-Q showed estimated backlog of about $266 million at April 3, 2026, while inventories rose to $346.7 million from $299.4 million at fiscal year-end and operating cash flow for the first six months was negative $17.6 million. Management said second-half fiscal 2026 revenue should be up about 3% year over year, but the longer thesis still depends on turning anticipated demand into shipments, cash generation, and better gross-margin performance. [#10-Q-2026-05-07] [#8-K-2026-05-07]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-08 • Updated nightlySource: Internal modelMethodology